These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19891598)

  • 1. Transcription factors as therapeutic targets in CNS disorders.
    Kane MJ; Citron BA
    Recent Pat CNS Drug Discov; 2009 Nov; 4(3):190-9. PubMed ID: 19891598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
    Amigoni F; Legnaghi E; Pevarello P
    Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS drug delivery systems: novel approaches.
    Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent patents on calcium channel blockers: emphasis on CNS diseases.
    Arranz-Tagarro JA; de los Ríos C; García AG; Padín JF
    Expert Opin Ther Pat; 2014 Sep; 24(9):959-77. PubMed ID: 25118673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders.
    Freeman RS; Barone MC
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):85-92. PubMed ID: 15723616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Neuroscience--Seventh Biennial FENS Forum.
    Hannan AJ
    IDrugs; 2010 Sep; 13(9):607-9. PubMed ID: 20799140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):731-3. PubMed ID: 19943210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription Factor Drug Targets.
    Papavassiliou KA; Papavassiliou AG
    J Cell Biochem; 2016 Dec; 117(12):2693-2696. PubMed ID: 27191703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sigma receptor modulators: a patent review.
    Collina S; Gaggeri R; Marra A; Bassi A; Negrinotti S; Negri F; Rossi D
    Expert Opin Ther Pat; 2013 May; 23(5):597-613. PubMed ID: 23387851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of agmatine for CNS disorders.
    Neis VB; Rosa PB; Olescowicz G; Rodrigues ALS
    Neurochem Int; 2017 Sep; 108():318-331. PubMed ID: 28522414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015).
    Singh IP; Shah P
    Expert Opin Ther Pat; 2017 Jan; 27(1):17-36. PubMed ID: 27623022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting transcription factors by small compounds--Current strategies and future implications.
    Hagenbuchner J; Ausserlechner MJ
    Biochem Pharmacol; 2016 May; 107():1-13. PubMed ID: 26686579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.
    Skaper SD; Walsh FS
    Mol Cell Neurosci; 1998 Nov; 12(4-5):179-93. PubMed ID: 9828084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aquaporin-4 water channel as a potential drug target in neurological disorders.
    Verkman AS; Smith AJ; Phuan PW; Tradtrantip L; Anderson MO
    Expert Opin Ther Targets; 2017 Dec; 21(12):1161-1170. PubMed ID: 29072508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.